Boehringer Ingelheim has posted a 4.1% rise in 2015 currency-adjusted sales, mainly thanks to a rapid acceleration in its diabetes drug ... a number of other products recently – Ofev for ...

Arnd Prilipp, Launch and Established Products CVM Boehringer Ingelheim. Diabetes is a chronic disease that occurs when the body doesn't properly produce, or use, the hormone insulin. It affects an ...

The CEO of pharmaceuticals giant Roche said authorities should block the takeover of contract drug manufacturer Catalent by ...

By Noah Weiland and Rebecca Robbins Hikma said it had reduced the cash portion of the offer as Boehringer Ingelheim’s generic drugs business in the U.S. had lower-than-expected sales.

Diabetic retinopathy appears to be more common in young people than earlier thought, leaving more of them at risk for eye ...

That's the same day Boehringer Ingeleim's out-of-pocket cost cap on all of its inhaler products will take effect. Boehringer ...

The U.S. FDA Breakthrough Therapy designation is for the treatment of adults with non-cirrhotic metabolic dysfunction-associated steatohepatitis ...

Boehringer Ingelheim, a leading research-driven biopharmaceutical company, hosted a dedicated event aimed at improving outcomes for patients living with cardiovascular, renal, and metabolic (CRM) ...

Find out how this could enhance access to quality healthcare, with an emphasis on mental health services for vulnerable populations.

Boehringer's Jardiance group of products, managed in a partnership with Eli Lilly, made 7.4 billion euros in annual sales, a currency-adjusted surge of 31%. Jardiance, used to treat diabetes ...